Overview Study of Safety and Tolerability of DCR HBVS Status: Active, not recruiting Trial end date: 2022-07-01 Target enrollment: Participant gender: Summary DCR-HBVS will be evaluated for safety and efficacy in healthy volunteers and chronic hepatitis B patients. Phase: Phase 1 Details Lead Sponsor: Dicerna Pharmaceuticals, Inc.